US Preclinical CRO Ricerca has launched two new assay services one of which is designed to help assess the risk a biologic drug will induce a cytokine storm.
BioFocus and Activiomics have teamed up to offer a drug discovery and biomarker service which it says will improve the identification of novel targets.
Granules India saw API sales rocket in the fiscal first quarter due – according to the firm – to an efficiency drive and the impact of rising prices in China.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
Reformulation and delivery tech firm SkyPharma is set for an earnings boost following US approval for rheumatoid arthritis (RA) drug developed by Horizon Pharma.
Pharmas producing drugs for the Australian market may see manufacturing licence charges slashed if their products do not sell above a certain threshold according to a plan outlined by the TGA.
in-PharmaTechnologist.com presents its weekly round-up of the latest chops and changes on the pharmaceutical careers ladder, including news from ABPI, Cubist and Oxford Pharmascience.
Covance has reported a net loss of $12.7m in this year’s Q2 as what it says is the result of facility closures and restructuring costs, particularly for its early phase development section.
Cherwell Laboratories has more than doubled the size of its Bicester, UK, plant that manufactures prepared media for microbial production after a boom in demand for its goods.
Teva Pharmaceuticals is set to build its first Indian production plant after finalising a pact with healthcare giant Procter & Gamble (P&G), according to local authorities.
The US Patient-Centered Outcomes Research Institute (PCORI) has suggested the pharmaceutical industry is introducing bias into clinical trials through selective use of inclusion/exclusion criteria and comparators.
Sigma Aldrich’s fine chemicals manufacturing section SAFC ensured a modest growth for the company although its “weak” research business in the US and the EU has stunted any drastic figures, according to analysts.
Aegis Therapeutics has been granted a US patent for a novel formulation method and excipient that it claims reduces the risk of oxidative damage during MAb production and storage.
The global CMO market will grow from $26bn in 2010 to $59.9bn by 2018 thanks to a boom in the amount of work outsourced to the Asia market, says GBI Research.
Four of the biggest pharma manufacturing associations are calling for more patient awareness of the burgeoning issue of fake drugs sold on the internet.
Parexel says EU trials directive never achieved harmonization aims and welcomes plans to simplify regulations, even if the implementation date is further away than expected.
SPIC has pressed the Indian PM to issue a standardised excise duty to all contract manufacturers operating in the country so drugsmakers can have a level playing field.
Outsourcing-Pharma.com presents its weekly low down of the movers and shakers in the world of pharmaceuticals, including news from Parexel, Ricerca, and CSC.
The billion dollar Korea Drug Development Fund (KDDF) has called on US CRO Parexel to help local developers commercialise pharmaceuticals on the global market.
More support for IPEC Americas’ proposed excipient safety review process emerged last week with Colorcon saying it makes Pharmas more likely to use new excipients.
Approval of Qsymia - Vivus’ anti-obesity drug – may be good news for the 35 per cent of US citizens classed as obese, but it is definitely good news for Taiwan-based CMO ScinoPharm.
The EC says proposals to replace the Clinical Trials Directive with simplified rules will make Europe more attractive for trials, but what do CROs think? Share your opinions in this exclusive Outsourcing-pharma.com poll.
API production in India will take a hit this week with plant closures for Aurobindo, Hetero Drugs, Divis Pharmaceuticals, and Sri Krishna Pharmaceuticals following allegations of environmental wrongdoing.
Two major takeovers dominate the headlines this week with GSK finally securing its takeover of HGS and Par Pharmaceutical agreeing to be bought by private-equity firm TGS.
DSM Pharmaceutical Products (DPP) has won its second biologics manufacturing contract in two months signing up Brazil’s Recepta Biopharma as a new customer.
in-PharmaTechnologist.com presents its weekly round-up of the latest movers and shakers in the world of pharmaceuticals, including news from Daiichi Sankyo, Galenea and Lannett.
BioFocus has taken on Titian’s sample management software in a bid to pump more resources into “refreshing” its 900,000 strong high-throughput screening (HTS) compound portfolio.
